Kazmira Joins ValidCare Clinical Safety Study for CBD ProductsKazmira and other CBD brands will assess CBD safety profiles with end-consumersKazmira, a technology based cannabinoid ingredient manufacturer, is partnering with ValidCare to participate in a large clinical safety study for CBD products. Kazmira joins the second cohort of brands participating in
Co-CEO & Co-Founder Dr. Priyanka Sharma spoke with Hemp Industry Daily on a roundtable with leaders and entrepreneurs throughout the industry.
They reflect on how COVID-19 has affected hemp and CBD companies, discussing the challenges, the changes, and the future of the industry.
Overview:
Cannabinoids are naturally present in low concentrations, and manufacturers must innovate in order to produce compliant natural extracts.
Chemical modification or synthesis processes are often used to mitigate the issues of low yield and THC compliance.
Consumers are unaware that chemical or synthetic processes are being used, and are often under the impression that their products were made using natural, hemp derived cannabinoids.
Manufacturers are not disclosing the presence of chemically modified or synthetic cannabinoids in their extracts.
Kazmira uses large scale extraction and separation science to purify the naturally occurring cannabinoids and
never uses synthetic compounds or processes to chemically modify our cannabinoids.